Your browser doesn't support javascript.
loading
Is rituximab sub-optimally dosed in indolent B cell lymphoma?
Sawalha, Yazeed; Rouphail, Basel; Jia, Xuefei; Dean, Robert M; Hill, Brian T; Jagadeesh, Deepa; Pohlman, Brad L; Smith, Mitchell R.
Afiliação
  • Sawalha Y; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
  • Rouphail B; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
  • Jia X; Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
  • Dean RM; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
  • Hill BT; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
  • Jagadeesh D; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
  • Pohlman BL; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
  • Smith MR; Department of Medical Oncology and Hematology, Taussig Cancer Institute, Cleveland, OH, USA.
Br J Haematol ; 174(5): 721-9, 2016 09.
Article em En | MEDLINE | ID: mdl-27136331

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Rituximab Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Rituximab Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos